Ulocuplumab is a fully humanized anti-CXCR4 monoclonal antibody with a longer half-life than plerixafor, which shows pro-apoptotic activity in the context of hematological malignancies [161]. This evidence concerns the gene CXCR4 and hematologic disorder.